Migraine Treatment Receives FDA Approval in the USA

Drug currently undergoing UK clinical trial at Re:Cognition Health

REYVOW (lasmiditan) is a migraine medication which is currently undergoing UK clinical trials at Re:Cognition Health in the LAIJ study. We are thrilled to announce that Eli Lily, the pharmaceutical company conducting this trial, has received FDA approval for the medication in the USA, meaning that it has proven to be a successful treatment in studies in the USA and will soon be available on the market to patients in the States.

Reyvow is a new treatment for acute migraines, an extremely painful condition which affects up to 6 million Britons each year. The efficacy of this treatment in the USA was demonstrated in two randomized, double-blind, placebo-controlled trials on 3,177 study volunteers. The medication targets pain and other migraine symptoms such as nausea, light and sound sensitivity. 


Migraine treatment experts welcome Reyvow

Whilst Reyvow is still undergoing UK and European studies, this approval is a huge step forward in treating people with acute migraine.

Dr Emer MacSweeney, Consultant Neuroradiologist at Re:Cognition Health comments, “It’s always fantastic news when a clinical trial has a successful outcome and we are delighted to hear that Reyvow has received FDA approval in the USA. We are optimistic that this treatment will have the same successful outcome in the UK studies. Our team of Brain & Mind Experts are proud to be giving LAIJ study volunteers in the UK the opportunity to be part of this extremely important research, as well giving them early access to this new-generation medication, which can be life-changing for many people who suffer from migraine attacks.”

Re:Cognition Health is committed to research and finding new treatments and ultimately a cure for migraine through our ongoing clinical trials. We are proud to be spearheading new studies such as LAIJ and helping improve the quality of life for millions of people worldwide. 


For further information about the LAIJ study and to register your interest to participate, please visit:

For further information on migraine management:


Back To All News